Skip to content

Disc Medicine IRON Accrued Expenses

Accrued Expenses at other companies

Protagonist Therapeutics logo
Protagonist TherapeuticsPTGX
$17.49M+47.7%
Agios Pharmaceuticals logo
Agios PharmaceuticalsAGIO
$11.69M+49.8%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$39.29M+30.0%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$2.1M-86.7%
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$39.34M+17.6%

Other financials

Income statement

See full
Operating income-$69.5M-74.0%
Net income-$63.5M-86.3%
EPS (diluted)-$1.65-61.8%

Balance sheet

See full
Cash & equivalents$88.9M-27.5%
Total debt$31.1M+1.4%
Total equity$688.4M+4.3%
Total assets$750.2M+5.8%

Cash flow

See full
Operating cash flow-$62.2M-50.4%
CapEx--100%
Free cash flow-$62.2M-47.4%

Valuation

See full
Market cap$2.69B+42.2%
Enterprise value$2.63B+46.7%

Returns & leverage

See full
Return on equity-35.8%+41.3pp
Debt / equity0.0×
Current ratio24×-13.6×

Where this comes from

Reported directly by Disc Medicine in its filing.

Tagged under the XBRL concept us-gaap:AccruedLiabilitiesCurrent.

The official record: Disc Medicine’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Disc Medicine's accrued expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Disc Medicine's accrued expenses?
Disc Medicine (IRON) reported accrued expenses of $6.83M in Q1 2026.
How has Disc Medicine's accrued expenses changed year-over-year?
Disc Medicine's accrued expenses increased by 65.0% year-over-year, from $4.14M to $6.83M.
What is the long-term trend for Disc Medicine's accrued expenses?
Over 5 years (2020 to 2025), Disc Medicine's accrued expenses has grown at a 99.5% compound annual growth rate (CAGR), from $492.59K to $15.56M.
What does accrued expenses mean?
Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.